Talk:Etozoline
This is the talk page for discussing improvements to the Etozoline redirect. This is not a forum for general discussion of the article's subject. |
Article policies
|
Find medical sources: Source guidelines · PubMed · Cochrane · DOAJ · Gale · OpenMD · ScienceDirect · Springer · Trip · Wiley · TWL |
![]() | Ideal sources for Wikipedia's health content are defined in the guideline Wikipedia:Identifying reliable sources (medicine) and are typically review articles. Here are links to possibly useful sources of information about Etozoline.
|
![]() | This redirect does not require a rating on Wikipedia's content assessment scale. It is of interest to the following WikiProjects: | ||||||||||||||||||||||||||||||
|
Requested move 10 July 2016
[edit]- The following is a closed discussion of a requested move. Please do not modify it. Subsequent comments should be made in a new section on the talk page. Editors desiring to contest the closing decision should consider a move review. No further edits should be made to this section.
The result of the move request was: Moved. This proposed move is uncontroversial and unopposed. -- Ed (Edgar181) 20:09, 19 July 2016 (UTC)
Etozoline → Etozolin – ETOZOLIN (without an «e») is the proper International Nonproprietary Name (INN) of this compound. Please look at the official document at http://www.who.int/medicines/publications/druginformation/innlists/RL06.pdf (page 5). You can also take a look at compounds’ PubChem page (https://pubchem.ncbi.nlm.nih.gov/compound/5743585) as well as ChemSpider one (http://www.chemspider.com/Chemical-Structure.4675409.html — click «More...» under «Names and Identifiers» and you’ll see: «Etozolin [USAN:INN]») vaccinationist (T) 10:01, 10 July 2016 (UTC) --Relisting. GeoffreyT2000 (talk) 02:07, 19 July 2016 (UTC)
- Support Pharmaceutical compounds are titled by the INN per WP:NCCHEM and WP:PHARMMOS. Plantdrew (talk) 18:44, 19 July 2016 (UTC)
- The above discussion is preserved as an archive of a requested move. Please do not modify it. Subsequent comments should be made in a new section on this talk page or in a move review. No further edits should be made to this section.